TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maximizing the Efficacy of Cognitive Behavioral Therapy With Medication and Contingency Management
Brief Summary: This is a study of four treatments for chronic cocaine use and may help study participants to control their drug use. All participants will receive weekly individual cognitive behavioral therapy (CBT).


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Disulfiram; Type: ACTIVE_COMPARATOR; Interventions: Drug: disulfiram | Arm Label: Placebo plus Contingency Management; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Placebo plus Contingency Management | Arm Label: Disulfiram plus Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Drug: Disulfiram plus Contingency Management | Intervention Type: DRUG; Name: disulfiram; Assigned to Arm(s): Disulfiram | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Placebo plus Contingency Management; Assigned to Arm(s): Placebo plus Contingency Management | Intervention Type: DRUG; Name: Disulfiram plus Contingency Management; Assigned to Arm(s): Disulfiram plus Contingency Management
B: Arm Label: Standard Care; Type: PLACEBO_COMPARATOR; Interventions: Other: Standard Care | Arm Label: Contingency management for abstinence from drugs; Type: EXPERIMENTAL; Interventions: Behavioral: contingency management | Intervention Type: BEHAVIORAL; Name: contingency management; Assigned to Arm(s): Contingency management for abstinence from drugs | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): Standard Care
C: Arm Label: Employment Only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Employment Only | Arm Label: Contingency Management; Type: EXPERIMENTAL; Interventions: Behavioral: Contingency management | Intervention Type: BEHAVIORAL; Name: Contingency management; Assigned to Arm(s): Contingency Management | Intervention Type: BEHAVIORAL; Name: Employment Only; Assigned to Arm(s): Employment Only
D: Arm Label: Referral to community resources; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Contingency Management; Type: EXPERIMENTAL; Interventions: Behavioral: Contingency management | Intervention Type: BEHAVIORAL; Name: Contingency management; Assigned to Arm(s): Contingency Management

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Brief Intervention for Drug Abusing Students
Brief Summary: The purpose of this clinical trail is to evaluate the efficacy of a brief, cognitive-behavioral therapeutic intervention for adolescents reporting mild or moderate drug abuse (MMDA). This school-based initiative employs a collaborative effort between the University of Minnesota researchers and the St. Paul Public Schools. This intervention aims to reduce post-treatment drug use behaviors and enhance drug-use resistant cognitions and problem-solving skills.


Options:
A: Arm Label: Family Function Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Familias Unidas | Arm Label: Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Familias Unidas; Assigned to Arm(s): Family Function Intervention
B: Arm Label: Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Family-Skills Training | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Family-Skills Training | Intervention Type: BEHAVIORAL; Name: Family-Skills Training; Assigned to Arm(s): Control Group, Intervention Group
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: brief intervention (cognitive-behavioral therapy) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: brief intervention (cognitive-behavioral therapy) | Intervention Type: BEHAVIORAL; Name: brief intervention (cognitive-behavioral therapy); Assigned to Arm(s): 1, 2
D: Arm Label: Örebro prevention program; Type: EXPERIMENTAL; Interventions: Behavioral: Örebro prevention program | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Business as usual | Intervention Type: BEHAVIORAL; Name: Örebro prevention program; Assigned to Arm(s): Örebro prevention program | Intervention Type: BEHAVIORAL; Name: Business as usual; Assigned to Arm(s): Control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Randomized Study of TLK286 (Telcyta®) in Combination With Liposomal Doxorubicin (Doxil/Caelyx)Versus Liposomal Doxorubicin (Doxil/Caelyx) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer (ASSIST-5)
Brief Summary: The purpose of this research study is to determine if Telcyta® given in combination with liposomal doxorubicin is more effective than liposomal doxorubicin alone in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer or primary peritoneal cancer that is refractory or resistant to platinum chemotherapy.


Options:
A: Arm Label: Ixabepilone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ixabepilone | Arm Label: Ixabepilone + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixabepilone, Drug: Bevacizumab | Intervention Type: DRUG; Name: Ixabepilone; Assigned to Arm(s): Ixabepilone, Ixabepilone + Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Ixabepilone + Bevacizumab
B: Arm Label: pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo comparator | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): pazopanib | Intervention Type: DRUG; Name: Placebo comparator; Assigned to Arm(s): placebo
C: Arm Label: BI 6727; Type: EXPERIMENTAL; Interventions: Drug: BI 6727 | Arm Label: Cytotoxic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Gemcitabine, Drug: Topotecan, Drug: Pegylated liposomal doxorubicin (PLD) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: Pegylated liposomal doxorubicin (PLD); Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: BI 6727; Assigned to Arm(s): BI 6727
D: Arm Label: Telcyta + Liposomal Doxorubicin; Type: EXPERIMENTAL; Interventions: Drug: Telcyta, Drug: Liposomal Doxorubicin | Arm Label: Liposomal Doxorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Intervention Type: DRUG; Name: Telcyta; Assigned to Arm(s): Telcyta + Liposomal Doxorubicin | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): Liposomal Doxorubicin, Telcyta + Liposomal Doxorubicin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Randomized Study of TLK286 (Telcyta®) in Combination With Liposomal Doxorubicin (Doxil/Caelyx)Versus Liposomal Doxorubicin (Doxil/Caelyx) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer (ASSIST-5)
Brief Summary: The purpose of this research study is to determine if Telcyta® given in combination with liposomal doxorubicin is more effective than liposomal doxorubicin alone in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer or primary peritoneal cancer that is refractory or resistant to platinum chemotherapy.


Options:
A: Arm Label: Telcyta + Liposomal Doxorubicin; Type: EXPERIMENTAL; Interventions: Drug: Telcyta, Drug: Liposomal Doxorubicin | Arm Label: Liposomal Doxorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Intervention Type: DRUG; Name: Telcyta; Assigned to Arm(s): Telcyta + Liposomal Doxorubicin | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): Liposomal Doxorubicin, Telcyta + Liposomal Doxorubicin
B: Arm Label: Vintafolide + PLD; Type: EXPERIMENTAL; Interventions: Drug: Vintafolide, Drug: pegylated liposomal doxorubicin (PLD), Other: EC20 | Arm Label: PLD Alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pegylated liposomal doxorubicin (PLD), Other: EC20 | Intervention Type: DRUG; Name: Vintafolide; Assigned to Arm(s): Vintafolide + PLD | Intervention Type: DRUG; Name: pegylated liposomal doxorubicin (PLD); Assigned to Arm(s): PLD Alone, Vintafolide + PLD | Intervention Type: OTHER; Name: EC20; Assigned to Arm(s): PLD Alone, Vintafolide + PLD
C: Arm Label: DOXIL + trabectedin; Type: EXPERIMENTAL; Interventions: Drug: Trabectedin, Drug: DOXIL, Drug: Dexamethasone | Arm Label: DOXIL; Type: ACTIVE_COMPARATOR; Interventions: Drug: DOXIL | Intervention Type: DRUG; Name: Trabectedin; Assigned to Arm(s): DOXIL + trabectedin | Intervention Type: DRUG; Name: DOXIL; Assigned to Arm(s): DOXIL, DOXIL + trabectedin | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): DOXIL + trabectedin
D: Intervention Type: DRUG; Name: TLK286; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Procalcitonin Guided Antibiotic Therapy and Hospitalisation in Patients With Lower Respiratory Tract Infections: The "ProHOSP" Study
Brief Summary: The aim of this study is to test if procalcitonin (PCT) guided antibiotic stewardship in patients with lower respiratory tract infection (LRTI) will be non-inferior, with at worst a 7.5% higher combined failure rate, as compared to standard care practice (current guidelines for LRTI) with reduced total antibiotic (AB) use and hospitalization rate and duration, respectively.


Options:
A: Arm Label: PCT; Type: EXPERIMENTAL; Interventions: Behavioral: a strategy based on PCT guided AB therapy | Arm Label: Guidelines; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: a strategy based on PCT guided AB therapy | Intervention Type: BEHAVIORAL; Name: a strategy based on PCT guided AB therapy; Assigned to Arm(s): Guidelines, PCT
B: Intervention Type: OTHER; Name: laboratory value procalcitonin; Assigned to Arm(s): N/A
C: Arm Label: PCT guided; Type: EXPERIMENTAL; Interventions: Procedure: Earlier therapeutic changes regarding infection | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Earlier therapeutic changes regarding infection | Intervention Type: PROCEDURE; Name: Earlier therapeutic changes regarding infection; Assigned to Arm(s): Control, PCT guided
D: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Procalcitonin Guided Antibiotic Therapy and Hospitalisation in Patients With Lower Respiratory Tract Infections: The "ProHOSP" Study
Brief Summary: The aim of this study is to test if procalcitonin (PCT) guided antibiotic stewardship in patients with lower respiratory tract infection (LRTI) will be non-inferior, with at worst a 7.5% higher combined failure rate, as compared to standard care practice (current guidelines for LRTI) with reduced total antibiotic (AB) use and hospitalization rate and duration, respectively.


Options:
A: Intervention Type: OTHER; Name: laboratory value procalcitonin; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Procalcitonin guided strategy | Intervention Type: PROCEDURE; Name: Procalcitonin guided strategy; Assigned to Arm(s): 1
C: Intervention Type: PROCEDURE; Name: PCT measurement; Assigned to Arm(s): N/A
D: Arm Label: PCT; Type: EXPERIMENTAL; Interventions: Behavioral: a strategy based on PCT guided AB therapy | Arm Label: Guidelines; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: a strategy based on PCT guided AB therapy | Intervention Type: BEHAVIORAL; Name: a strategy based on PCT guided AB therapy; Assigned to Arm(s): Guidelines, PCT

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2b Extension Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis
Brief Summary: In some patients with cystic fibrosis (CF), the disease is caused by a nonsense mutation (premature stop codon) in the gene that makes the cystic fibrosis transmembrane regulator (CFTR) protein. PTC124 has been shown to partially restore CFTR production in animals with CF due to a nonsense mutation. In an ongoing Phase 2a study being performed at the Hadassah University Hospital - Mount Scopus in Israel, patients with nonsense-mutation-mediated CF have received PTC124 in two 14-day treatment courses. Preliminary results from that study indicate that PTC124 has pharmacodynamic activity of PTC124 in CF and that PTC124 can be safely administered in this patient population. This Phase 2b extension study is designed to evaluate the activity and safety of 3 months (approximately 84 days) of continuous treatment with PTC124 in the same patients who were enrolled to the Phase 2a study. The main purpose of this study is to understand whether PTC124 can be safely administered and achieve pharmacodynamic activity in patients with CF due to a nonsense mutation.


Options:
A: Arm Label: PTC124 PO; Type: EXPERIMENTAL; Interventions: Drug: PTC124 | Intervention Type: DRUG; Name: PTC124; Assigned to Arm(s): PTC124 PO
B: Arm Label: Ataluren; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ataluren; Assigned to Arm(s): Ataluren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
D: Arm Label: Ataluren 4, 4, and 8 mg/kg, then ataluren 10, 10, and 20 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Arm Label: Ataluren 10, 10, and 20 mg/kg, then ataluren 4, 4, and 8 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Intervention Type: DRUG; Name: Ataluren; Assigned to Arm(s): Ataluren 10, 10, and 20 mg/kg, then ataluren 4, 4, and 8 mg/kg, Ataluren 4, 4, and 8 mg/kg, then ataluren 10, 10, and 20 mg/kg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open Label Comparative Study to Determine the Proportion of Asthma Patients on SERETIDE Diskus 50/250 mcg b.i.d. Achieving Total Control When Given Medication and Compliance Enhancement Training Compared to Those Receiving Medication Only
Brief Summary: This study will investigate whether study subjects with previously uncontrolled asthma treated with SERETIDE Diskus 50/250 CCI18781+GR33343 mcg twice a day can attain a level of Total Control of their condition and whether adherence to treatment can be enhanced by teaching the subjects. Two groups of equal size with identical medical treatment will be compared with each other, the test group receiving three training modules during study visits and the control group regular study visits only.


Options:
A: Arm Label: CALMA; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CALMA plus, Behavioral: CALMA | Arm Label: Calma plus; Type: EXPERIMENTAL; Interventions: Behavioral: CALMA plus | Intervention Type: BEHAVIORAL; Name: CALMA plus; Assigned to Arm(s): CALMA, Calma plus | Intervention Type: BEHAVIORAL; Name: CALMA; Assigned to Arm(s): CALMA
B: Arm Label: I; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback of patient adherence information | Arm Label: II; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active control group | Intervention Type: BEHAVIORAL; Name: Feedback of patient adherence information; Assigned to Arm(s): I | Intervention Type: BEHAVIORAL; Name: Active control group; Assigned to Arm(s): II
C: Arm Label: Interventional group: Period 2; Type: EXPERIMENTAL; Interventions: Drug: salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training | Arm Label: Control group: Period 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: salmeterol/fluticasone propionate 50/250 µg | Arm Label: Subjects receiving salmeterol/fluticasone propionate: Period 1; Type: EXPERIMENTAL; Interventions: Drug: salmeterol/fluticasone propionate 50/250 µg | Intervention Type: DRUG; Name: salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training; Assigned to Arm(s): Interventional group: Period 2 | Intervention Type: DRUG; Name: salmeterol/fluticasone propionate 50/250 µg; Assigned to Arm(s): Control group: Period 2, Subjects receiving salmeterol/fluticasone propionate: Period 1
D: Arm Label: mailed information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: mailed information | Arm Label: community health worker; Type: EXPERIMENTAL; Interventions: Behavioral: community health worker | Intervention Type: BEHAVIORAL; Name: community health worker; Assigned to Arm(s): community health worker | Intervention Type: BEHAVIORAL; Name: mailed information; Assigned to Arm(s): mailed information

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy of Spinal Cord Stimulation at Varying Stimulation Frequencies and Pulse-Widths
Brief Summary: The purpose of the study is to measure the efficacy of varying spinal cord stimulation frequencies and pulse-width settings on chronic pain management. The spinal cord stimulator settings that are most effective in chronic pain management hope to be revealed for the purposes of this study. In this double-blind study, both the patient and the staff will not be aware of the spinal cord stimulator settings for each patient each week. The representative that will set the settings each week will be blinded to the identity of each patient and will set the spinal cord stimulator from another room. While there are few papers that show the efficacy of spinal cord stimulation in treating chronic pain, there has yet to be a study performed that measures the role of stimulation frequency and pulse-widths. This study hopes to be the first.


Options:
A: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A
C: Intervention Type: DEVICE; Name: Medtronic Manufactured Spinal Cord Stimulators; Assigned to Arm(s): N/A
D: Arm Label: Spinal Cord Stimulation; Type: EXPERIMENTAL; Interventions: Procedure: Spinal Cord Stimulation | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Spinal Cord Stimulation; Assigned to Arm(s): Spinal Cord Stimulation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy of Spinal Cord Stimulation at Varying Stimulation Frequencies and Pulse-Widths
Brief Summary: The purpose of the study is to measure the efficacy of varying spinal cord stimulation frequencies and pulse-width settings on chronic pain management. The spinal cord stimulator settings that are most effective in chronic pain management hope to be revealed for the purposes of this study. In this double-blind study, both the patient and the staff will not be aware of the spinal cord stimulator settings for each patient each week. The representative that will set the settings each week will be blinded to the identity of each patient and will set the spinal cord stimulator from another room. While there are few papers that show the efficacy of spinal cord stimulation in treating chronic pain, there has yet to be a study performed that measures the role of stimulation frequency and pulse-widths. This study hopes to be the first.


Options:
A: Arm Label: EES on; Type: EXPERIMENTAL; Interventions: Device: EES on | Arm Label: EES off; Type: PLACEBO_COMPARATOR; Interventions: Device: EES off | Intervention Type: DEVICE; Name: EES on; Assigned to Arm(s): EES on | Intervention Type: DEVICE; Name: EES off; Assigned to Arm(s): EES off
B: Intervention Type: DEVICE; Name: Medtronic Manufactured Spinal Cord Stimulators; Assigned to Arm(s): N/A
C: Arm Label: CMM; Type: OTHER; Interventions: Other: CMM | Arm Label: HF10 + CMM; Type: ACTIVE_COMPARATOR; Interventions: Device: HF10 Therapy, Other: CMM | Intervention Type: DEVICE; Name: HF10 Therapy; Assigned to Arm(s): HF10 + CMM | Intervention Type: OTHER; Name: CMM; Assigned to Arm(s): CMM, HF10 + CMM
D: Arm Label: Tonic; Type: EXPERIMENTAL; Interventions: Procedure: dorsal column stimulator | Arm Label: Sham; Type: EXPERIMENTAL; Interventions: Procedure: dorsal column stimulator | Arm Label: burst; Type: EXPERIMENTAL; Interventions: Procedure: dorsal column stimulator | Intervention Type: PROCEDURE; Name: dorsal column stimulator; Assigned to Arm(s): Sham, Tonic, burst

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy of Spinal Cord Stimulation at Varying Stimulation Frequencies and Pulse-Widths
Brief Summary: The purpose of the study is to measure the efficacy of varying spinal cord stimulation frequencies and pulse-width settings on chronic pain management. The spinal cord stimulator settings that are most effective in chronic pain management hope to be revealed for the purposes of this study. In this double-blind study, both the patient and the staff will not be aware of the spinal cord stimulator settings for each patient each week. The representative that will set the settings each week will be blinded to the identity of each patient and will set the spinal cord stimulator from another room. While there are few papers that show the efficacy of spinal cord stimulation in treating chronic pain, there has yet to be a study performed that measures the role of stimulation frequency and pulse-widths. This study hopes to be the first.


Options:
A: Arm Label: Burst spinal cord stimulation (SCS); Type: EXPERIMENTAL; Interventions: Procedure: Burst Spinal Cord Stimulation, Procedure: Sham spinal cord stimulation | Arm Label: sham spinal cord stimulation (SCS); Type: SHAM_COMPARATOR; Interventions: Procedure: Burst Spinal Cord Stimulation, Procedure: Sham spinal cord stimulation | Intervention Type: PROCEDURE; Name: Burst Spinal Cord Stimulation; Assigned to Arm(s): Burst spinal cord stimulation (SCS), sham spinal cord stimulation (SCS) | Intervention Type: PROCEDURE; Name: Sham spinal cord stimulation; Assigned to Arm(s): Burst spinal cord stimulation (SCS), sham spinal cord stimulation (SCS)
B: Arm Label: Evoke SCS with Feedback; Type: EXPERIMENTAL; Interventions: Device: Evoke Spinal Cord Stimulator (SCS) System | Arm Label: Evoke SCS with Conventional; Type: ACTIVE_COMPARATOR; Interventions: Device: Evoke Spinal Cord Stimulator (SCS) System | Intervention Type: DEVICE; Name: Evoke Spinal Cord Stimulator (SCS) System; Assigned to Arm(s): Evoke SCS with Conventional, Evoke SCS with Feedback
C: Arm Label: SHAM; Type: SHAM_COMPARATOR; Interventions: Device: Spinal cord stimulation | Arm Label: High Density Stimulation; Type: EXPERIMENTAL; Interventions: Device: Spinal cord stimulation | Arm Label: Conventional stimulation; Type: ACTIVE_COMPARATOR; Interventions: Device: Spinal cord stimulation | Intervention Type: DEVICE; Name: Spinal cord stimulation; Assigned to Arm(s): Conventional stimulation, High Density Stimulation, SHAM
D: Intervention Type: DEVICE; Name: Medtronic Manufactured Spinal Cord Stimulators; Assigned to Arm(s): N/A

Answer: D